CEACAM5 and neoplasm: Two well-studied TAAs for PDAC and ovarian cancer, MUC16, and CEACAM5, illustrate the two principal challenges of targeting non-mutated TAAs: difficulty in breaking T-cell tolerance and, conversely, the potential for induction of on-target off-tumor toxicities.